Newron Pharmaceuticals SpA NWPHF:Grey Market

*Data is delayed | Exchange | USD
Last | 01/18/24 EDT
8.52UNCH (UNCH)
52 week range
5.22 - 8.55
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close8.52
  • 52 Week High8.55
  • 52 Week High Date01/16/24
  • 52 Week Low5.22
  • 52 Week Low Date12/26/23

Key Stats

  • Market Cap147.64M
  • Shares Out17.85M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change63.22

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close8.52
  • 52 Week High8.55
  • 52 Week High Date01/16/24
  • 52 Week Low5.22
  • 52 Week Low Date12/26/23
  • Market Cap147.64M
  • Shares Out17.85M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change63.22

RATIOS/PROFITABILITY

  • EPS (TTM)-1.00
  • P/E (TTM)-8.49
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Newron Pharmaceuticals SpA

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the...
Ulrich Kostlin
Non-Executive Independent Chairman of the Board
Stefan Weber
Chief Executive Officer, Executive Director
Dennis Dionne
Vice President - Commercial Affairs
Roberto Galli
Vice President - Finance
Address
via Antonio Meucci 3
Bresso
20091
Italy